HGH Growth Hormone

Human Growth hormone or HGH or hGH

August 1st, 1996, the FDA approved Humatrope (injectable) SOMATROPIN, BIOSYNTHETIC 5MG/VIAL for the use in treatment of adult onset or childhood onset adult HGH deficiency. Now HGH can be prescribed for hormonal deficient adults.

In 1990, the New England Journal of Medicine released an article by D Rudman, AG Feller, HS Nagraj, GA Gergans, PY Lalitha, AF Goldberg, RA Schlenker, L Cohn, IW Rudman, and DE Mattson about "Effects of human growth hormone in men over 60 years old".

It said:
Abstract:
The declining activity of the growth hormone insulin-like growth factor I (IGF-I) axis with advancing age may contribute to the decrease in lean body mass and the increase in mass of adipose tissue that occur with aging.
Methods:
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six month base line period and a six month treatment period that followed. During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic HGH per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment. Plasma IGF-I levels were measured monthly. At the end of each period we measured lean body mass, the mass of adipose tissue, skin thickness (epidermis plus dermis), and bone density at nine skeletal sites.
Results:
In group 1, the mean plasma IGF-I level rose into the youthful range of 500 to 1500 U per liter during treatment, whereas in group 2 it remained below 350 U per liter. The administration of HGH for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P<0.05 in each instance). Skin thickness increased 7.1 percent (P=0.07). There was no significant change in the bone density of the radius or proximal femur. In group 2 there was no significant change in lean body mass, the mass of adipose tissue, skin thickness, or bone density during treatment.
Conclusions:
Diminished secretion of HGH is responsible in part for the decrease of lean body mass, the expansion of adipose-tissue mass, and the thinning of the skin that occur in old age. (N Engl J Med 1990; 323:1-6.)

Oral Spray hGH
FTC Stops False Claims

More Info

Partners

Copyright &
Disclaimer Info
© HGHStudy.com
2003/2011